What Is Impassion130

Impassion130 is a major clinical trial that tested a new approach to treating triple negative breast cancer. The study combined atezolizumab, an immunotherapy drug, with standard chemotherapy to see if this combination worked better than chemotherapy alone.

Triple negative breast cancer is particularly challenging because it lacks three common protein markers. This makes traditional hormone-based treatments ineffective, requiring researchers to explore alternative approaches like immunotherapy to help patients.

How Impassion130 Trial Works

The Impassion130 study design involved multiple phases where researchers tracked patient responses carefully. Participants received either the atezolizumab combination or standard chemotherapy, allowing scientists to compare treatment outcomes directly.

Throughout the trial, medical teams monitored how well tumors responded and tracked side effects in both groups. This rigorous approach provided clear data about whether adding immunotherapy to chemotherapy offered real advantages for patients dealing with this aggressive cancer type.

Key Treatment Protocol Details

The Impassion130 treatment protocol specified exact dosages and administration schedules for all participants. Patients received their assigned therapy in cycles, with breaks between treatments to allow their bodies to recover.

Medical teams conducted regular assessments to measure tumor shrinkage and monitor overall health. This structured approach ensured consistent data collection and allowed researchers to identify patterns in how different patients responded to the combined therapy regimen.

Clinical Trial Results and Patient Outcomes

The Impassion130 study results showed meaningful improvements when atezolizumab was added to chemotherapy. Patients receiving the combination demonstrated better progression-free survival rates compared to those on chemotherapy alone, according to research published by Roche, which developed atezolizumab.

These patient outcomes represented a significant step forward in triple negative breast cancer treatment. The data suggested that immunotherapy could help the body's immune system work more effectively against cancer cells, leading to better response rates and extended survival periods for many participants in the trial.

Understanding Side Effects and Benefits

Like all cancer treatments, the Impassion130 immunotherapy approach came with potential side effects that patients needed to consider. Common reactions included fatigue, fever, and immune-related complications, though most were manageable with proper medical support.

The benefits, however, often outweighed these challenges for eligible patients. The combination approach offered hope for individuals with aggressive triple negative breast cancer, where treatment options had previously been more limited. Healthcare providers worked with patients to weigh the potential advantages against possible side effects when deciding if this approach was appropriate.

Conclusion

The Impassion130 clinical trial data represents an important milestone in cancer treatment development. By demonstrating that combining immunotherapy with traditional chemotherapy could improve outcomes for triple negative breast cancer patients, this research expanded treatment possibilities for a particularly challenging form of cancer. Patients and healthcare providers can reference these Impassion130 trial outcomes when making informed decisions about treatment approaches. The success of this study highlights how innovative combinations of existing therapies can create meaningful progress in the fight against cancer.

Citations

  • https://www.roche.com

This content was written by AI and reviewed by a human for quality and compliance.